Image by Freepik
UC Davis’ pioneering work in comparative oncology continues with the establishment of the Canine Tumor Genome Atlas, the first genomic data bank of its kind outside of the National Cancer Institute. It could eventually hold hundreds of gene samples from companion canines suffering osteosarcomas, oral melanomas, and gliomas.
These three malignancies are strikingly similar to those found in humans, and tragically, they can be fatal in both species. Scientists use comparative oncology to uncover remedies that work in dogs in the expectation that comparable medications may work in humans. In fact, canine clinical studies to evaluate an immunotherapy drug for cancer are currently underway at UC Davis.
The UC Davis Comprehensive Cancer Center is creating an enormous genome database as part of its collaborative cancer study with the UC Davis School of Veterinary Medicine in order to map why particular canines are genetically prone to cancer. Researchers hope that by assisting in the discovery of cancer therapies for pets, the atlas may lead to comparable breakthroughs for people with cancer.
“These genomics studies will show how tumors mutate and what’s driving those mutations in the cancerous cells.”—John McPherson
The study endeavor is led by John McPherson, deputy director of the cancer center, and Christine Toedebusch, assistant professor of surgery and radiological sciences at the UC Davis veterinary school. It is supported by a $115,000 cancer center grant.
“These genomics studies will show how tumors mutate and what’s driving those mutations in the cancerous cells,” McPherson said.
The Canine Tumor Genome Atlas will house biological samples containing mutations and changes in tumor gene expression. After the genetic makeup of the tumors has been studied and sequenced, the atlas will allow researchers to mine the data.
“Think of it this way,” McPherson said. “A genome is like an encyclopedia set. Every volume of the encyclopedia is a chromosome and inside every volume are chapters and paragraphs. Sequencing is reading the words and letters of the genome. As a genomic researcher, I’m looking at misspelled words. These are changes that alter the function of proteins encoded by the genes.”
According to McPherson, this study strategy, known as oncogenetics, will use the atlas to find gene variants that stand out like sore fingers, and then track those patterns to see whether they can be matched to specific tumors.
“Our canine companions share genetic and environmental complexity with us and have an intact immune system, unlike laboratory mice,” Toedebusch said. “Many canine tumors progress similarly and share many features with human tumors. While laboratory mice are vital to initially understand and test mechanisms of cancer progression, they have repeatedly demonstrated limited success in therapeutic translation to human cancer patients. Naturally occurring canine cancer may serve as a bridge for therapeutic translation between rodents and humans.”
“Many canine tumors progress similarly and share many features with human tumors.”—Christine Toedebusch
Toedebusch, for example, stated that gliomas are lethal brain tumors in dogs and humans, with patients dying within a year to 18 months of diagnosis.
“It has been more than 20 years since a new therapy has been effective at extending this meager survival time in humans,” Toedebusch said. “Companion canines with glioma are becoming more readily acceptable as a translational model for human glioma, creating funding opportunities to study the canine disease and allowing for the possibilities of breakthroughs in treating canines and humans, alike.”
The Canine Tumor Genome Atlas will be shared with other cancer researchers around the country.
more recommended stories
Air Pollution Hurts Brain Health in Just 4 HoursAir Pollution Blurs the Mind, Impairs.
New therapies developed by Oxford experts offer online support for anxiety and post-traumatic stress disordersUrgent treatment solutions are needed for.
three key pillars to tackle antimicrobial resistance effectively — University of Oxford, Medical Sciences DivisionThe High-Level Meeting on antimicrobial resistance.
Oxford Vaccine Group marks 30 years battling ‘deadly six’ diseases with major art installation — University of Oxford, Medical Sciences DivisionThe installation was commissioned to mark.
Professor Ahmed Awarded Funding To Create World’s First Ovarian Cancer Prevention Vaccine — University of Oxford, Medical Sciences DivisionScientists at the University of Oxford,.
New research network unites Oxford University’s global fight against antimicrobial resistance — University of Oxford, Medical Sciences DivisionAntimicrobial resistance (AMR) threatens the foundation.
Typhoid vaccine trial confirms sustained protection for older children — University of Oxford, Medical Sciences DivisionThe TyVOID study, published in the Lancet, measured the.
Study Publishes New Insights on Goblet Cell Differentiation in Colorectal Cancer — University of Oxford, Medical Sciences DivisionThe research addresses the long-recognized poor.
Four Oxford researchers win prestigious Philip Leverhulme Prizes — University of Oxford, Medical Sciences DivisionOnly 30 prizes are awarded throughout.
Kavli Oxford’s Nick Gatford Wins Image of Distinction Award in Nikon Small World Competition — University of Oxford, Medical Sciences DivisionThe Nikon Small World competition, often.
Leave a Comment